Verteporfin
Recommended OphthalmologyRestrictedNot applicable line
Treatment of subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration where the CNV is composed predominantly (≥50%) of classic lesions, as defined by fluorescein angiography.
1
Submissions
2005–05
On the record
$45k–75k
ICER range
1 sourced ICER · 2005
ICER stated
Cost basis
Decision on record
- Meeting Nov 2007 Recommended Macular degeneration no PSD
Access path
- Nov 2005Recommended · restricted
vs standard care (no treatment or watchful waiting)
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
The PBAC considered that the incremental cost per extra QALY gained at between $45,000 to $75,000 (excluding cost offsets) was high but acceptable and less uncertain than the estimated cost-effectiveness for the additional patient groups requested for subsidy. PBAC · 2005
ICER uncertainCost-effectiveness accepted
Decision context
PopulationPatients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration where the CNV is composed predominantly (≥50%) of classic lesions as defined by fluorescein angiography.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2005 | Recommended · restricted | standard care (no treatment or watchful waiting) | $45k–75k | RCT · Loss of less than 15 letters of visual acuity |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to AMD with ≥50% classic lesions by FA; TGA label includes occult and other macular diseases without this requirement.